Cytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir Therapy

Journal of Heart and Lung Transplantation

Volumn 28, Issue 7, 2009, Pages 670-675

  Jaksch, Peter ^a   Zweytick, Barbara ^a   Kerschner, Heidrun ^b   Hoda, Ali Mir ^a   Keplinger, Maya ^a   Lang, György ^a   Aigner, Clemens ^a   Klepetko, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INCIDENCE; INFECTION PREVENTION; LEUKOPENIA; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 67649097086     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.03.012     Document Type: Article

References (42)

1. Keller C.A., Cagle P.T., Brown R.W., et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 107 (1995) 973-980
2. Keenan R.J., Lega M.E., Dummer J.S., et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 51 (1991) 433-438
3. Alexander B.D., and Tapson V.F. Infectious complications of lung transplantation. Transplant Infect Dis 3 (2001) 128-137
4. Fishman J.A., Emery V., Freeman R., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21 (2007) 149-158
5. Zamora M.R. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transplant Infect Dis 3 suppl 2 (2001) 49-56
6. Duncan S.R., Grgurich W.F., Iacono A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 150 (1994) 146-152
7. Gerbase M.W., Dubois D., Rothmeier C., et al. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 116 (1999) 1265-1272
8. Gutierrez C.A., Chaparro C., Krajden M., et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 113 (1998) 924-932
9. Soghikian M.V., Valentine V.G., Berry G.J., et al. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 15 (1996) 881-887
10. Speich R., Thurnheer R., Gaspert A., et al. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 67 (1999) 315-320
11. Weill D., Lock B.J., Wewers D.L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 3 (2003) 492-496
12. Wreghitt T.G., Abel S.J., McNeil K., et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transplant Int 12 (1999) 254-260
13. Valentine V.G., Weill D., Gupta M.R., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 27 (2008) 875-881
14. Pescovitz M.D., Pruett T.L., Gonwa T., et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 66 (1998) 1104-1107
15. Pescovitz M.D., Rabkin J., Merion R.M., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44 (2000) 2811-2815
16. Zamora M.R., Davis R.D., and Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80 (2005) 157-163
17. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 (2004) 1635-1642
18. - solid organ transplant recipients. Am J Transplant 4 (2004) 644-649
19. Humar A., Kumar D., Preiksaitis J., et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 5 (2005) 1462-1468
20. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
21. Husain A.N., Siddiqui M.T., Holmes E.W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 159 (1999) 829-833
22. Rubin R.H. Importance of CMV in the transplant population. Transplant Infect Dis 1 suppl 1 (1999) 3-7
23. Danziger-Isakov L.A., DelaMorena M., Hayashi R.J., et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 75 (2003) 1538-1543
24. Zeevi A., Uknis M.E., Spichty K.J., et al. Proliferation of cytomegalovirus-primed lymphocytes in bronchoalveolar lavages from lung transplant patients. Transplantation 54 (1992) 635-639
25. Pouteil-Noble C., Ecochard R., Landrivon G., et al. Cytomegalovirus infection-an etiological factor for rejection?. A prospective study in 242 renal transplant patients. Transplantation 55 (1993) 851-857
26. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340 (1999) 1462-1470
27. Flint A. Frank TS. Cytomegalovirus detection in lung transplant biopsy samples by polymerase chain reaction. J Heart Lung Transplant 13 (1994) 38-42
28. Arbustini E., Morbini P., Grasso M., et al. Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung. Molecular, immunocytochemical, and histopathologic investigations. Transplantation 61 (1996) 418-427
29. Cainelli F., and Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship?. Lancet Infect Dis 2 (2002) 539-549
30. Duncan A.J., Dummer J.S., Paradis I.L., et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 10 (1991) 638-644
31. Smyth R.L., Scott J.P., Higenbottam T.W., et al. Experience of cytomegalovirus infection in heart-lung transplant recipients. Transplant Proc 22 (1990) 1820-1821
32. Ettinger N.A., Bailey T.C., Trulock E.P., et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis 147 (1993) 1017-1023
33. Tamm M., Aboyoun C.L., Chhajed P.N., et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 170 (2004) 1120-1123
34. Luckraz H., Sharples L., McNeil K., et al. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant 22 (2003) 287-291
35. Kroshus T.J., Kshettry V.R., Savik K., et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 114 (1997) 195-202
36. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81 (2006) 1415-1420
37. Kruger R.M., Shannon W.D., Arens M.Q., et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68 (1999) 1272-1279
38. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11 (2001) 83-86
39. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 32 (2001) 742-751
40. Hart G.D., and Paya C.V. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11 (2001) 73-81
41. Limaye A.P., Raghu G., Koelle D.M., et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185 (2002) 20-27
42. Aigner C., Jaksch P., Winkler G., et al. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Wien Klin Wochenschr 117 (2005) 480-484